

…at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

ABOUT HANSA BIOPHARMA

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company's lead product, imlifidase, is an antibody-degrading enzyme being developed to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansa's research and development program is advancing the next generation of the Company's enzyme technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the US.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES

Candidate	Indication	Research/ Preclinical	Phase 1	Potentially Pivotal program/ Phase 2	Phase 3	Marketing Authorization	Marketed
Imlifidase	**EU** Kidney transplantation in highly sensitized patients [1,2]					*)	
	US Kidney transplantation in highly sensitized patients [1,2]				**)		
	Anti-GBM antibody disease (investigator-initiated study)						
	Antibody mediated kidney transplant rejection (AMR)						
	GBS (Guillain Barre Syndrome)						
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology						
EnzE	Cancer immunotherapy						

Completed
Ongoing

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
*) EMA: Positive CHMP opinion received June 2020 for a conditional approval – Formal adoption by the EU Commission expected Q3 2020, while a post-approval study will commence in parallel with the launch
**) FDA: Agreement with the FDA on a regulatory path forward in the US. New clinical study could support BLA submission by 2023. Safety review of an Investigational New Drug application (IND) expected in Q3 2020, while the study is expected to be initiated Q4 2020

STRATEGIC PRIORITIES

- Establish a commercial and medical infrastructure in Europe
- Attain marketing authorization in Europe for imlifidase as a treatment for highly sensitized patients to enable kidney transplantation. Conduct a new randomized, controlled study in the US in the context of KAS to support a BLA filing by 2023
- Investigate the potential of imlifidase in autoimmune indications and post transplantation
- Advance a new set of immunomodulatory enzymes designed for repeat dosing in relapsing diseases (NiceR) into clinical development
- Explore potential combination therapies with imlifidase in oncology and in gene therapy in patients with neutralizing antibodies

ANTICIPATED FUTURE MILESTONES



*Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund

Updated 2020-07-16

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden
www.hansabiopharma.com

HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	~80 (~2/3 in R&D)
Key Executives	Ulf Wiinberg, Chairman
	Søren Tulstrup, President & CEO
	Donato Spota, SVP & CFO
	Christian Kjellman, SVP & CSO/COO

MARKET DATA (July 2020)

Market Cap	SEK ~10bn (USD ~1bn)	
52 Week Range	SEK 59-282	
Avg. Daily Turnover	vol. 327k shares	
Shares Outstanding	~45m	
Top 5 Shareholders	NXT2B	14.4%
	Consonance Capman	6.2%
	Invesco	5.0%
	Thomas Olausson	4.3%
	Gladiator	3.1%

STOCK CHART (1Y)



KEY FINANCIALS

SEKm	2018	2019	H1 2020*
Revenue	3m	3m	1.5m
R&D cost	-155m	-193m	-106m
Net loss	-248m	-360m	-193m
Cash & Short investment	858m	601m	400m**
Operating Cash Flow	-205m	-335m	-199m
Employees	52	74	78

** Unaudited ** Excluding 1,112 MSEK capital raise and 10m USD Sarepta license agreement upfront payment*

CALENDAR

Jul 16, 2020	**Interim Report Jan – Jun 2020**
Aug 14, 2020	Nordea Small & Mid Cap Seminar, Stockholm
Sep 1, 2020	Kempen Road Show, Paris & Tel Aviv (virtual)
Sep 3, 2020	Pareto Healthcare Conf, Stockholm
Sep 15, 2020	Morgan Stanley Global Healthcare Conf, NYC
Sep 16, 2020	BofAML Global Healthcare Conf, London
Sep 23, 2020	ABG Small & Mid Cap Seminar, CPH
Oct 22, 2020	**Interim Report Jan-Sep 2020**
Oct 29, 2020	**Hansa Biopharma Capital Markets Day (TBD)**
Nov 25, 2020	Ökonomisk Ugebrev Life Science Conf, CPH

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269
klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corp. Comms.
M: +46(0)768-198 326
katja.margell@hansabiopharma.com

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATE PATHOGENIC IgG

Origins from Streptococcus pyogenes



Imlifidase, a unique IgG antibody-cleaving enzyme



Imlifidase inactivates IgG in 2 hours



OUR EQUITY STORY

Targeting rare immunologic diseases with a unique IgG antibody-cleaving enzyme, addressing a high unmet medical need

Preparing for potential European launch of imlifidase following potential conditional approval in 2020. Positive CHPM opinion received June 2020. Formal adoption by the EU Commission expected in Q3 2020

Evolution into a fully integrated biopharmaceutical company. We control the full value chain from early discovery through commercialization to maximize the value creation and capture

Leveraging our proprietary antibody cleaving enzyme technology. We are advancing our pipeline with three phase 2 programs in transplantation and acute autoimmune diseases

A new set of modified enzymes is under development (NiceR) for repeat dosing; potentially enabling treatment in relapsing diseases and oncology

We are exploring potential combination therapies in oncology and gene therapy in patients with neutralizing antibodies through potential partnerships



POTENTIAL INDICATION UNIVERSE



HANSA BIOPHARMA